Levels of CD40 expression on dendritic cells dictate tumour growth or regression

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 194-202

  Murugaiyan, G ^a   Martin, S ^a   Saha, B ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Anti tumour immunotherapy; CD40; Co stimulation; Dendritic cells

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 12; KEYHOLE LIMPET HEMOCYANIN; LYMPHOCYTE SURFACE MARKER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON TYPE II; INTERLEUKIN-10; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 34250214974     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03407.x     Document Type: Article

References (25)

1. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996 56 : 1909 16.
2. Funakoshi S, Longo DL, Beckwith M et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994 83 : 2787 94.
3. van Mierlo GJ, den Boer AT, Medema JP et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002 99 : 5561 6.
4. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004 173 : 5923 8.
5. Geldart T, Illidge T. Anti-CD 40 monoclonal antibody. Leuk Lymph 2005 46 : 1105 13.
6. Mortarini R, Borri A, Tragni G et al. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving IL-12. Cancer Res 1998 60 : 3559 68.
7. Tatsumi T, Takehara T, Kanto T et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 2001 61 : 7563 7.
8. Hanks BA, Jiang J, Singh RA et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005 11 : 130 7.
9. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 2001 98 : 10811 6.
10. Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B. Functional dichotomy in CD40 reciprocally regulates effector T cell functions. J Immunol 2006 177 : 6642 9.
11. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002 101 : 61 8.
12. Walker SR, Redlinger RE Jr., Barksdale EM Jr. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 2005 40 : 244 9.
13. French LE, Huard B, Wysocka M et al. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood 2005 105 : 219 25.
14. Ahuja SS. In vitro generation of functional human and murine DCs. Meth Mol Biol 2002 156 : 67 77.
15. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996 184 : 747 52.
16. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Meth 1991 145 : 185 92.
17. Kelsall BL, Stuber E, Neurath M, Strober W. Interleukin-12 production by DCs. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann NY Acad Sci 1996 795 : 116 26.
18. Mackey MF, Barth RJ Jr., Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998 63 : 418 28.
19. D'Amico G, Vulcano M, Bugarin C et al. CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy. Blood 2004 104 : 744 51.
20. Schmidt CS, Mescher MF. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J Immunol 2002 163 : 2561 7.
21. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 2002 169 : 6842 9.
22. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003 197 : 1141 51.
23. Fontana S, Moratto D, Mangal S et al. Functional defects of dendritic cells in patients with CD40 deficiency. Blood 2003 102 : 4099 106.
24. Murugaiyan G, Basak S, Saha B. Reversal of tumor induced dendritic cell paralysis: a treatment regimen against cancer. Curr Immunol Rev 2006 2 : 261 72.
25. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 2004 10 : 540 4 [erratum in Nat Med 2004; 10: 755].